Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress [Yahoo! Finance]
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: Yahoo! Finance
AnaptysBio (ANAB) has drawn fresh attention after reporting a profitable fourth quarter and a sharply smaller full year loss, helped by collaboration revenues, milestone payments, and higher royalties tied to GSK's cancer drug Jemperli. See our latest analysis for AnaptysBio. The stock's sharp 1 year total shareholder return of about 2.5x, together with a 90 day share price return of 29.15% and 27.43% year to date, suggests momentum has been building around the recent earnings turnaround, royalty progress on Jemperli and the planned spin off of First Tracks Biotherapeutics, even after a 5.40% one day pullback to US$57.28. If this earnings jump has you looking across biotech, it could be a good moment to scan other potential immunology and oncology stories with our 32 healthcare AI stocks With earnings swinging to a quarterly profit, royalties tied to Jemperli scaling, and the share price already up multiple times over 1 year, is AnaptysBio still mispriced, or is the market al
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- AnaptysBio (ANAB) was given a new $50.00 price target by Truist Financial Corporation.MarketBeat
- AnaptysBio (ANAB) had its price target raised by Stifel Nicolaus from $56.00 to $85.00. They now have a "buy" rating on the stock.MarketBeat
- AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- AnaptysBio (ANAB) had its price target raised by Barclays PLC from $78.00 to $79.00. They now have an "overweight" rating on the stock.MarketBeat
- AnaptysBio (ANAB) had its price target raised by HC Wainwright from $51.00 to $66.00. They now have a "buy" rating on the stock.MarketBeat
ANAB
Earnings
- 3/3/26 - Beat
ANAB
Sec Filings
- 3/3/26 - Form 10-K
- 3/3/26 - Form 8-K
- 2/13/26 - Form 4
- ANAB's page on the SEC website